Aelin Therapeutics off to a flying start

The biotech newcomer Aelin Therapeutics, based on research from VUB, KU Leuven and UGent (VIB), has secured a starting capital of €27 million. It is the largest starting capital ever for a spin-off of VIB. The company will use the proceeds of the money, to bring a first Pept-in product to the clinic.

Read the full articles in De Standaard, Trends en op VIB.